In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...
Like the find-and-replace feature of a word processor, CRISPR-based engineering allows scientists to quickly and efficiently edit DNA sequences with base pair precision. Lauded as the great ...
Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer. As researchers have learned more and more about the cancer-immune system interplay, ...
The colonies of Escherichia coli sitting in this petri dish become pathogenic when they carry Shiga toxin genes. Credit: Shutterstock “We’re essentially converting a pathogenic strain into a ...
CRISPR has a problem: an embarrassment of riches. Ever since the gene editing system rocketed to fame, scientists have been looking for variants with better precision and accuracy. One search method ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results